Objectives To estimate the number of new cases of age-related macular degeneration, cataract and glaucoma accruing in the UK Biobank cohort, over a period of 25 years from time of recruitment. Our secondary objective was to assess the statistical power of nested case-control studies of these eye diseases. We aimed to provide quantitative information relevant to UK Biobank's eye disease case ascertainment efforts and to the potential for UK Biobank-based research into the causes of eye disease. Methods We constructed a Markov discrete-time state transition model to simulate the population dynamics of the eye disorders within the UK Biobank cohort, using prevalence data from population-based epidemiological studies to derive incidence, and Office for National Statistics data on mortality and migration overseas.
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Objectives To estimate the number of new cases of age-related macular degeneration, cataract and glaucoma accruing in the UK Biobank cohort, over a period of 25 years from time of recruitment. Our secondary objective was to assess the statistical power of nested case-control studies of these eye diseases. We aimed to provide quantitative information relevant to UK Biobank's eye disease case ascertainment efforts and to the potential for UK Biobank-based research into the causes of eye disease. Methods We constructed a Markov discrete-time state transition model to simulate the population dynamics of the eye disorders within the UK Biobank cohort, using prevalence data from population-based epidemiological studies to derive incidence, and Office for National Statistics data on mortality and migration overseas. results By 2023, >900 new cases of each of 'wet' (neovascular) and 'dry' age-related macular degeneration, >1200 cases of primary open angle glaucoma and almost 15 000 cases of cataracts are expected to have accrued in the subcohort of 68 500 participants who had ocular assessment at baseline, with around seven times as many cases of each disease in the whole cohort of 500 000 participants. These predicted incident case numbers generate good or substantial statistical power for a range of nested case-control studies of potential genetic, lifestyle and environmental determinants of disease. Conclusions Over the next few years, UK Biobank is expected to generate sufficient numbers of new cases for statistically well-powered studies of the determinants of the major causes of sight loss: age-related macular degeneration, vision-impairing cataract and glaucoma.
InTrOduCTIOn

UK Biobank (UKB)
1 2 is a large, prospective, population-based study of over 500 000 UK adults aged between 40 and 69 years at recruitment between 2006 and 2010. It contains extensive phenotype and genetic data from all participants, with ongoing longitudinal follow-up mainly through linkage to national healthcare databases. It is an open-access resource for approved researchers nationally and internationally to investigate determinants of a wide range of health-related outcomes. During recruitment, a comprehensive phenotypic assessment of eye health was carried out in a subset of 68 500 participants-here referred to as the 'ocular subcohort'-enabling investigation into the major sight-threatening conditions developing during the course of long-term follow-up.
Cataract, age-related macular degeneration (AMD) and primary open-angle glaucoma (POAG) are major causes of sight loss in adults. Cataract remains the leading cause of blindness in low-income and middle-income countries, and a major cause of visual impairment requiring surgery throughout the world. AMD and POAG are major causes of eye morbidity and loss of vision in high-income countries. Despite substantial investment in epidemiological and basic science research into these disorders in the past three decades, there remain important gaps in our knowledge 3 4 including the aetiology of cataract in people with diabetes (which is expected to increase in prevalence as obesity rates continue to rise); the association of genetic, environmental and behavioural factors with the risk of developing age-related cataract or AMD; and common risk factors for AMD and other diseases of ageing that affect the central nervous system, such as Alzheimer's disease.
Previous reports 5 6 have estimated the distribution over time of incident cases predicted to occur in UKB for a range of chronic diseases considered to be of particular public health importance, and the statistical power profile of nested case-control studies that may use data from the UKB cohort. Estimates for eye diseases were not included.
Estimating the likely burden of common eye conditions in the UKB cohort is important in order to (1) provide information about the potential statistical power of future studies, for example, nested case-control studies, and (2) plan suitable scalable methods to ascertain, confirm and subclassify eye disorders for such studies.
We provide here estimates for the number of incident cases of AMD, 'age-related' cataract and POAG expected to occur among UKB participants over a period of 25 years from recruitment.
MeThOds
Analysis model
For the main analysis, a Markov model was constructed to represent a discrete-time state transition model, with a 'cycle' length of 1 year. This was designed to simulate the population dynamics of the eye disorder within the UKB cohort, monitoring changes in prevalent numbers, year by year over the projection period of 25 years, keeping a count of new cases being generated (incidence) and changes in the number of cohort members at risk (attrition). Figure 1 Examples of smoothing age-specific prevalence data: (A) exponential curve fitted to observed neovascular age-related macular degeneration (NV AMD) prevalence by age, for men 11 ; (B) logistic curve fitted to the observed cataract prevalence by age, for women.
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Attrition of the uKb cohort
In all the analyses of incidence, the expected attrition of the cohort over the projection period was taken into account. In addition to loss due to mortality, two other causes of attrition were considered: (1) migration overseas and (2) withdrawal from the study, where the participant wishes no further contact with UKB AND indicates that no further attempt is to be made to follow-up their health through linkage with healthcare information systems. 5 6 In both cases, the participant's future health status would be unavailable (or inaccessible to researchers) through linkage to UK routine health information systems.
Population mortality rates were obtained from the UK Office for National Statistics (ONS) 7 for the years 2006-2033. To reflect the 'healthy volunteer' effect, the UK population mortality rates were reduced by factors derived from an analysis of standardised mortality ratios (details in online supplementary file). Long-term international migration (outflow) data were obtained from the ONS. 8 Rates derived from these were used in our model. Based on UKB's experience to date, withdrawal was assumed to be low at 1 in 1000 per year.
Prevalence
For estimating prevalence, best available published age-specific and gender-specific prevalence proportions judged to be most appropriate for our purpose were used. These were selected through a review of large population-based prevalence studies or meta-analyses conducted by research teams with recognised expertise in survey methodology and ocular disease epidemiology. Given that 95% of the UKB cohort was white Caucasian, 9 preference was given to studies of UK or predominantly Caucasian populations, which used clear and appropriate case definitions, and included estimates for specified age classes up to and beyond age 79 years. The prevalence estimates [10] [11] [12] [13] [14] were mostly available by 5-year or 10-year age classes and were 'smoothed' through fitting of logistic or exponential curves to give figures for each 'exact' age, before application to the cohort (details in online supplementary file).
AMD prevalence
Case definition: AMD in either eye of persons aged 50 or older. AMD as defined by the International Age-Related Maculopathy Study Group 10 includes the two types: NV (neovascular) AMD and GA (geographic atrophy) AMD. Persons classified as having NV AMD had NV change in either eye. Similarly, those classified as GA AMD had GA in either eye. Consequently, a small number of individuals who had NV change in one eye and GA in the fellow eye were counted in both categories.
For AMD, our main source of prevalence data came from a meta-analysis of six major population-based studies in Europe, Australia and the USA. 11 Taking NV AMD in men as an example, figure 1a shows the observed age group-specific prevalence data and the exponential curve fitted to the values. The 'smoothed' prevalence data also provided the basis for derivation of incidence by 1-year age classes.
In a sensitivity analysis, we also considered a second source of prevalence data published in 2012. 12 This more recent study adopted a Bayesian meta-analytic approach, using data from 25 published studies employing various classification systems with much diversity and heterogeneity of prevalence rates across the studies. The focus of the study was assessment of age and gender variations in AMD prevalence (estimation of ORs), with careful adjustment for the effect of other study characteristics.
Cataract prevalence
Case definition: lens opacity causing impaired visual acuity of poorer than 6/12 (with correction), or pseudophakia/aphakia, in either eye of persons aged 40 years or older.
Source material most suitable for our purposes came from a population-based epidemiological study in North London, 13 providing age-specific and gender-specific prevalence data for 'vision-impairing lens opacity' (reducing visual acuity to poorer than 6/12, or pseudophakia/aphakia). As an example, figure 1b shows the observed age group-specific prevalence data and the logistic curve fitted to the values for women. The resulting prevalence proportions were applied in the model, as described above for AMD.
POAG prevalence
Case definition: POAG diagnosis based on visual fields assessment.
The source material comprised age-specific and gender-specific prevalence estimates for predominantly Caucasian populations from a recent meta-analysis 14 using a statistical model, standardising to studies that employed visual fields assessment on all participants to diagnose POAG. These prevalence estimates by 1-year age classes were used in our model as described for cataract and are displayed in online supplementary figure 1.
Incidence
There were no published incidence rate data suitable for our purpose. Based on previously described procedures, 15 16 our method used age-specific prevalence data (for men and women separately) to derive number of incident cases expected to occur in each year of follow-up (details are provided in the online supplementary file). figure 2 . By the 25th year of follow-up, 25% of the original cohort is expected to be lost to follow-up through death, migration or withdrawal. The number of new cases of AMD expected to accrue over a period of 25 years from recruitment in the ocular subcohort and in the whole study are shown in table 1. The predicted cumulative numbers of new cases in the whole cohort were around 4000 NV AMD and 3100 GA AMD by 2018, increasing to 16 600 NV AMD and 13 000 GA AMD by 2028, with around 14% of these cases occurring in the ocular subcohort. Re-running the model in a sensitivity analysis using the alternative source of age-specific prevalence data showed very similar estimates for GA AMD and around 20% fewer cases of NV AMD at each time point (table 1 and online supplementary figure 2).
New cases of cataract expected to accumulate over the projection period are shown in table 2 and in online supplementary figure 3 . The expected cumulative numbers of new cases of cataract in the whole cohort were around 24 800 by 2013, increasing to 61 000 by 2018, with around 14% of these cases occurring in the ocular subcohort. The expected cumulative number of new cases of POAG by 2013 was around 2200 in the whole cohort, increasing to over 5000 by 2018, with over 700 being within the ocular subcohort by this time (table 2 and online supplementary figure 4). Table 3 shows examples of statistical power that could be achieved by nested case-control studies for a range of plausible scenarios. It displays the smallest ORs that could be detected with powers of 80% and 90%, for a wide range of sample sizes, assuming various critical P values (0.05, 0.01 and 5.00E−08), under a range of scenarios regarding the frequency of exposure in cases and in controls.
statistical power
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dIsCussIOn From these projections, the UKB is expected to generate in timely fashion large numbers of new cases within the whole cohort providing substantial power for nested case-control studies to detect small ORs, and reasonable numbers giving adequate power for detection of moderate ORs for the particularly well-phenotyped ocular subcohort. The expected numbers of incident cases reported here are relevant in situations where the researcher can obtain all the required exposure data from the UKB, and the disease status data from linkage to healthcare information systems, without having to contact the UKB participant.
In research situations where direct contact is necessary, the available number of new cases may be smaller due to non-response. Nevertheless, by the year 2021, the ocular subcohort would have generated at least 700 new cases of NV AMD, even when the more conservative estimates based on our sensitivity analysis are used. Even assuming an under-ascertainment of 20% (assuming that not all of the expected new cases could be identified), the UKB cohort would still have sufficient power to detect moderate effects. By the same year, the whole cohort would have generated almost 5000 new cases of NV AMD, making it possible to detect smaller effect sizes. By the year 2010, more than 1000 new cases of cataract would have accrued in the ocular subcohort alone, and by 2018 more than 5000 new cases of POAG would have accumulated in the whole cohort, with over 700 being within the ocular subcohort, with the added advantage of detailed baseline ocular phenotyping. The results are encouraging for studies of the genetic determinants of eye diseases, showing good statistical power for the detection of moderate effects of genetic variants in genome-wide association studies (table 3) .
strengths and limitations
These projections of the number of likely new cases of a range of common eye disorders over the follow-up period of UKB will enable researchers to plan studies that investigate their genetic and environmental determinants. Validation of these estimates will be borne out through future studies involving data linkage to national healthcare and relevant administrative databases and analysis of available phenotypic data. These estimates are subject to a range of uncertainties and should therefore be seen as approximate rather than accurate predictions. The main determinants of the projected number of new cases were the source prevalence and mortality data used in our model. Other less important factors influencing the projected number of new cases included migration overseas and complete withdrawal (details in online supplementary file).
The mortality data in our model were based on the Principal projections provided by the ONS, rather than those based on High mortality assumptions, as these account for improvements in expected survival year-on-year throughout the projection period, although they may be somewhat optimistic. The age-specific prevalence data for cataract outcomes was based on data from the North London Eye Study, 13 it being the only published source suitable for our purposes. As this population-based study was conducted in the late 1990s, it is possible that the increase in cataract surgery rates since then would result in fewer numbers with cataract who have not had surgery. This, however, is not expected to affect the prevalence estimates of the combined cataract+aphakia or pseudophakia used in our model. We have no evidence that the risk factor profile for cataract or the underlying age-specific and gender-specific risk of developing cataract has changed materially since the late 1990s. This study only included subjects aged 65 or older, but as this age group covered the main bulk of the cataract cases, our extrapolation to ages below 65 is unlikely to have distorted our estimates of incident cases materially. For AMD, we used two data sources: the first with more uniformity in survey methodology and providing more precise (narrower 95% CI) estimates, 11 and the second employing a more advanced analytical approach, allowing us to generate a range of plausible estimates. 12 For POAG, we used the latest published data that provided prevalence estimates by age, gender and ethnicity.
14 These estimates could be taken to relate to 'definite' POAG diagnosed through assessment of the visual fields.
COnClusIOns
The UKB cohort is expected to generate sufficient numbers of new cases during follow-up to 2021 for statistically well-powered nested case-control studies of AMD, vision-impairing cataract and POAG, which are the leading causes of sight loss in the ageing population. Our findings demonstrate the importance of UKB as a resource for research into determinants of the major eye diseases associated with serious visual impairment and blindness. Furthermore, the ocular subcohort could provide data on disease severity/stage and phenotypes, for research into rates of disease progression and related risk or protective factors, for example, for progression of early maculopathy to AMD, and for ocular hypertension to POAG. The ocular subcohort is also a resource for exploring possible association of eye disease phenotypes with a wide range of other system disorders such as neurodegenerative diseases.
